WHO approves trials for two new Ebola vaccines

The World Health Organization (WHO) has officially approved the commencement of clinical trials for two new candidate vaccines designed to combat the Bundibugyo strain of Ebola. This regulatory step occurs as research into treatment options continues to advance in response to the current health crisis. One of the specific candidates selected for these trials is a vaccine developed by Moderna, which has been picked to enter Phase 2/3 testing. These efforts are specifically directed at the 2026 Bundibugyo Ebola disease outbreak, as the global health community seeks to establish effective immunization protocols for this particular strain of the virus. Coverage of this development is widespread across several major news and health organizations.

Al Jazeera and the World Health Organization have both confirmed the approval of these new trials, while Seeking Alpha highlighted the specific involvement of Moderna and the financial context of the Phase 2/3 trial. Additionally, The Independent has provided reporting on the various treatments currently being developed to address the Bundibugyo strain. The reporting emphasizes a coordinated effort to expand the available arsenal of medical interventions as the outbreak persists throughout the region. Context for these trials is provided by ReliefWeb, which has highlighted significant access gaps and provided recommendations regarding vaccines for the 2026 Bundibugyo Ebola disease outbreak. The necessity for these new trials stems from the specific nature of the Bundibugyo strain and the urgency of filling existing gaps in vaccine accessibility.

Because the outbreak is active in 2026, the approval of new candidates represents a critical shift toward expanding the scope of preventative medicine available to affected populations and healthcare workers on the front lines. Moving forward, the primary focus remains on the progress of the Phase 2/3 trials for the Moderna vaccine and the broader research into treatments for the Bundibugyo strain. Observers will be monitoring the results of these new candidate vaccines as they join the ongoing trial process. The global health community is also looking toward the implementation of the recommendations provided by ReliefWeb to address the noted access gaps. Further updates will depend on the clinical outcomes of these WHO-approved trials and the speed at which treatments can be deployed to the outbreak zones.